Sumitomo Pharma Co., Ltd.
SMDPY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $808 | $108,002 | $105,649 | $112,434 |
| % Growth | -99.3% | 2.2% | -6% | – |
| Cost of Goods Sold | $309 | $44,112 | $39,671 | $41,439 |
| Gross Profit | $499 | $63,890 | $65,978 | $70,995 |
| % Margin | 61.7% | 59.2% | 62.5% | 63.1% |
| R&D Expenses | $63 | $8,175 | $13,126 | $10,467 |
| G&A Expenses | $0 | $0 | $4,346 | $0 |
| SG&A Expenses | $277 | $35,657 | $49,565 | $41,044 |
| Sales & Mktg Exp. | $0 | $0 | $25,000 | $0 |
| Other Operating Expenses | $0 | -$342 | -$12,291 | -$1,921 |
| Operating Expenses | $341 | $43,490 | $50,400 | $49,590 |
| Operating Income | $158 | $20,400 | $15,578 | $21,405 |
| % Margin | 19.5% | 18.9% | 14.7% | 19% |
| Other Income/Exp. Net | $391 | -$8,468 | -$21,993 | $35,027 |
| Pre-Tax Income | $548 | $11,932 | -$6,415 | $56,432 |
| Tax Expense | -$46 | $726 | -$8,830 | $2,984 |
| Net Income | $594 | $11,206 | $2,415 | $53,448 |
| % Margin | 73.6% | 10.4% | 2.3% | 47.5% |
| EPS | 1.5 | 28.21 | 6.08 | 134.53 |
| % Growth | -94.7% | 364% | -95.5% | – |
| EPS Diluted | 1.5 | 28.21 | 6.08 | 134.53 |
| Weighted Avg Shares Out | 397 | 397 | 397 | 397 |
| Weighted Avg Shares Out Dil | 397 | 397 | 397 | 397 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $0 | $0 | $35,027 |
| Interest Expense | $0 | $8,468 | $21,993 | $0 |
| Depreciation & Amortization | $36 | $5,203 | $5,807 | $6,066 |
| EBITDA | $584 | $26,241 | $5,604 | $27,471 |
| % Margin | 72.3% | 24.3% | 5.3% | 24.4% |